Importance of the field: High mortality rates with cancers warrant further development of
earlier diagnostics and better treatment strategies. Membrane-bound erythropoietin …

The Eph receptor tyrosine kinases and ephrin ligands have been studied extensively for
their roles in developmental processes. In recent years, Eph receptors and ephrins have …

The EphA2 receptor is found at high levels in tumors and low levels in normal tissue and
high EphA2 expression in biopsies is a predictor of poor outcome in patients. Drug discovery …

In the realm of soft nanotechnology, hydrogel micro‐and nanoparticles represent a versatile
class of responsive materials. Over the last decade, our group has investigated the synthesis …

Erythropoietin-producing human hepatocellular receptors (EPHs) compose the largest
known subfamily of receptor tyrosine kinases (RTKs). They bind and interact with the EPH …

Background: Metastatic prostate cancer (PCa) has no curative treatment options. Some
forms of PCa are indolent and slow growing, while others metastasise quickly and may …

Background Targeting the cell-surface receptor EphA2, which is highly expressed in some
solid tumors, is a novel approach for cancer therapy. We aimed to evaluate the safety profile …

Bladder cancer is associated with high recurrence and mortality rates. These tumors show
vast heterogeneity reflected by diverse morphologic manifestations and various molecular …

Background: EphA2 is an oncoprotein and tyrosine kinase receptor that is overexpressed in
ovarian and many other cancers. We investigated the effects of reduced EphA2 levels on …

Background Urinary extracellular vesicles (uEVs) secreted from bladder cancer contain
cancer-specific proteins that are potential diagnostic biomarkers. We identified and …